Why the study?
The utility of the systemic immune-inflammatory index (SII) in estimating in-hospital and long-term prognosis in elderly patients with AMI receiving PCI needed assessment.
Does a higher systemic immune-inflammatory index (SII) predict worse clinical outcomes in elderly patients with acute myocardial infarction receiving percutaneous coronary intervention?
Does a higher systemic immune-inflammatory index (SII) predict worse clinical outcomes in elderly patients with acute myocardial infarction receiving percutaneous coronary intervention?
The systemic immune-inflammatory index (SII) is a readily available laboratory marker that independently predicts in-hospital and long-term mortality and MACCE in elderly patients with AMI undergoing PCI.
Answers are grounded in this paper and cite their sources.
SII may aid risk stratification in elderly AMI patients after PCI; hypothesis-generating for targeted interventions.
BACKGROUND We assessed the utility of the systemic immune-inflammatory index (SII) in estimating the in-hospital and long-term prognosis of elderly patients with acute myocardial infarction (AMI) who received percutaneous coronary intervention (PCI). MATERIAL AND METHODS Our study evaluated 711 consecutive elderly patients (age 65-85 years) from January 2015 to December 2017. The correlation between clinical outcomes and SII was analyzed through the stepwise Cox regression analysis and the Kaplan-Meier approach. The clinical endpoints were all-cause mortality and major adverse cardiovascular and cerebrovascular events (MACCE) in-hospital and during 3-year follow-up. RESULTS The study enrolled 711 elderly patients with AMI (66.95% male, 71.99±0.19 years). Kaplan-Meier analysis showed a lower survival rate in patients with higher SII scores, which also predicted in-hospital and long-term (≤3 years) outcomes. In multivariate analyses, SII showed an independent predictive value for in-hospital mortality (hazard ratio (HR), 3.32; 95% confidence interval (CI), 1.55-7.10; p<0.01), in-hospital MACCE (HR, 1.43; 95%CI, 1.02-2.00; p=0.04), long-term mortality (HR, 1.95; 95%CI, 1.23-3.09; p<0.01), along with long-term MACCE (HR, 1.72; 95%CI, 1.23-2.40; p<0.01). Moreover, SII showed a weak but significant positive relationship with the Gensini score among patients developing non-ST-segment elevation myocardial infarction (r=0.18; p<0.01). CONCLUSIONS SII, a readily available laboratory marker, is a potential indicator to predict the clinical endpoints for elderly patients with AMI undergoing PCI.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: